Today: 7 July 2026
Voyager Technologies stock jumps again on ISS drug-discovery deal, Wedbush call — what to watch next
25 January 2026
1 min read

Voyager Technologies stock jumps again on ISS drug-discovery deal, Wedbush call — what to watch next

New York, Jan 25, 2026, 09:24 EST — Market closed

  • Shares jumped 7.4% on Friday, sealing a two-day winning streak
  • Voyager’s ISS payload deal and a new Wedbush initiation kept interest alive in the recent listing
  • Next up for investors: February conference appearances, where updates on pipeline and execution are expected

Shares of Voyager Technologies Inc closed Friday up 7.4% at $37.09, after fluctuating between $34.62 and $38.84. Trading volume hovered near 3.0 million shares.

The stock continues to act like a fresh IPO: sharp swings, little tolerance, and a market hungry for confirmation. At the moment, traders are focusing on two immediate catalysts — a fresh space-medicine deal linked to the International Space Station and a bullish sell-side upgrade.

Voyager announced this week it secured a contract with Space LiinTech to send a new payload to the ISS focused on microgravity-enabled drug discovery. This research leverages near-weightless conditions in orbit to alter material formation. “Microgravity changes crystallization, growth dynamics and material properties at a fundamental level,” said Matt Magaña, president of Space, Defense & National Security at Voyager, in the statement. Voyager Technologies

Voyager will handle mission integration and payload configuration for Space LiinTech’s protein crystallization experiments—a key technique in drug research—under the new contract, the company stated. The mission will feature an AI-powered automation and monitoring system. Byungho Kim of Space LiinTech described the deal as “the start of a strong, long-term partnership,” according to the release. Voyager Technologies

Wedbush kicked off coverage on Friday, assigning an Outperform rating alongside a $46 price target — predicting where the stock might land within a year.

In a separate regulatory filing, Liberty Street Advisors reported holding 681,748 Voyager shares worth roughly $17.8 million as of Dec. 31. This indicates the stock is beginning to appear in some focused portfolios.

The recent rally gained momentum as defense and space stocks rallied on Friday. Booz Allen Hamilton surged following its earnings report and raised guidance, while Voyager pushed higher after revealing its ISS payload plans, according to IBD.

Voyager priced its U.S. IPO at $31 per share in June 2025, pulling in roughly $382.8 million, according to Reuters.

But there’s a catch to the run-up. Voyager hasn’t revealed the financial details of its Space LiinTech deal, leaving investors to wait and see if the ISS payload work leads to follow-up missions and steady revenue instead of just one-off news grabs.

Looking ahead to this week, all eyes turn to Voyager’s public remarks. The company is set to appear at multiple February conferences, kicking off with the TD Cowen Aerospace & Defense Conference on Feb. 13. Barclays and Citi events follow, wrapping up with the NYSE Space Summit on Feb. 23.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • General Dynamics (GD) Edges RTX for Value Investors on Core Metrics
    July 7, 2026, 1:24 PM EDT. General Dynamics (GD) and RTX both carry a Zacks Rank #2 (Buy), signaling better earnings outlooks. Still, value investors looking at P/E, P/B, and PEG ratios will see GD stand out. GD's forward P/E sits at 22.72, while RTX posts 29.13. PEG for GD is 2.34, lower than RTX's 2.85. Zacks gives GD a Value grade of B, above RTX's C. Both names belong in the aerospace and defense patch, but GD's valuation numbers look stronger.
Intuitive Surgical stock slips into weekend after earnings beat, with tariffs and 2026 outlook in focus
Previous Story

Intuitive Surgical stock slips into weekend after earnings beat, with tariffs and 2026 outlook in focus

Nestle stock faces Monday test after France probes baby deaths tied to recalled formula
Next Story

Nestle stock faces Monday test after France probes baby deaths tied to recalled formula

Go toTop